Longboard Pharmaceuticals, Inc.
NASDAQ:LBPH
59.98 (USD) • At close November 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Longboard Pharmaceuticals, Inc. |
Symbool | LBPH |
Munteenheid | USD |
Prijs | 59.98 |
Beurswaarde | 2,341,960,906 |
Dividendpercentage | 0% |
52-weken bereik | 59.98 - 59.98 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Kevin R. Lind |
Website | https://www.longboardpharma.com |
An error occurred while fetching data.
Over Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)